NextCell Pharma AB (NXTCL.ST)
Stockholm · SEK · Healthcare · Biotechnology
SEK 0.3015 (-29.72%) as of
Key statistics
- Market cap
- 38.11M
- EPS (TTM)
- -0.4300
- Dividend yield
- 0.00%
- 52-week range
- 0.2905 – 1.7840
- Beta
- 0.68
- Revenue (TTM)
- 10.78M
- Profit margin
- 0.00%
- Analyst target
- SEK 2.90
- Volume
- 6.15M
About NextCell Pharma AB
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank; and QVance, the first dedicated provider of quality services for developers of advanced therapies. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Huddinge, Sweden
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.